KR20070050934A - Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법 - Google Patents

Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법 Download PDF

Info

Publication number
KR20070050934A
KR20070050934A KR1020077004665A KR20077004665A KR20070050934A KR 20070050934 A KR20070050934 A KR 20070050934A KR 1020077004665 A KR1020077004665 A KR 1020077004665A KR 20077004665 A KR20077004665 A KR 20077004665A KR 20070050934 A KR20070050934 A KR 20070050934A
Authority
KR
South Korea
Prior art keywords
hiv
cell
cells
treatment
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077004665A
Other languages
English (en)
Korean (ko)
Inventor
베르너 크라우쎄
Original Assignee
바이엘 쉐링 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 쉐링 파마 악티엔게젤샤프트 filed Critical 바이엘 쉐링 파마 악티엔게젤샤프트
Publication of KR20070050934A publication Critical patent/KR20070050934A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020077004665A 2004-08-30 2005-07-28 Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법 Withdrawn KR20070050934A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60517304P 2004-08-30 2004-08-30
US60/605,173 2004-08-30

Publications (1)

Publication Number Publication Date
KR20070050934A true KR20070050934A (ko) 2007-05-16

Family

ID=35079284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077004665A Withdrawn KR20070050934A (ko) 2004-08-30 2005-07-28 Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법

Country Status (14)

Country Link
US (1) US20060057620A1 (https=)
EP (1) EP1784217A1 (https=)
JP (1) JP2008511559A (https=)
KR (1) KR20070050934A (https=)
AU (1) AU2005279460A1 (https=)
BR (1) BRPI0514729A (https=)
CA (1) CA2570735A1 (https=)
IL (1) IL179856A (https=)
MX (1) MX2007002188A (https=)
NO (1) NO20071700L (https=)
RU (1) RU2393872C2 (https=)
TW (1) TW200626172A (https=)
WO (1) WO2006024354A1 (https=)
ZA (1) ZA200702654B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor

Also Published As

Publication number Publication date
US20060057620A1 (en) 2006-03-16
WO2006024354A1 (en) 2006-03-09
ZA200702654B (en) 2008-08-27
CA2570735A1 (en) 2006-03-09
AU2005279460A1 (en) 2006-03-09
NO20071700L (no) 2007-05-29
IL179856A0 (en) 2007-05-15
EP1784217A1 (en) 2007-05-16
TW200626172A (en) 2006-08-01
JP2008511559A (ja) 2008-04-17
BRPI0514729A (pt) 2008-06-24
RU2393872C2 (ru) 2010-07-10
IL179856A (en) 2010-11-30
MX2007002188A (es) 2007-10-16
RU2007111566A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
Margolis et al. HIV antibodies for treatment of HIV infection
Wykes et al. Immune checkpoint blockade in infectious diseases
Lee et al. Antibody-dependent cellular cytotoxicity against reactivated HIV-1-infected cells
Richard et al. BST-2 expression modulates small CD4-mimetic sensitization of HIV-1-infected cells to antibody-dependent cellular cytotoxicity
Clutton et al. Diverse impacts of HIV latency-reversing agents on CD8+ T-cell function: implications for HIV cure
US20150031739A1 (en) Panobinostat for use in the treatment of hiv-1
KR20070050934A (ko) Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법
Igarashi et al. Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes
US20080233128A1 (en) Treatment of Viral Infections
US20160108122A1 (en) Therapeutic or prophylactic agent for immunodeficiency virus infection
Castellví Characterization of cellular factors involved in HIV-1 pathogenesis with potential therapeutic implications in viral infections and cancer
Pierce Jr Mucosal Viruses and Where to Find Them: Novel Insights into the Interactions of HsSV-2 and SARS-CoV-2 with the Host Immune System
JPH05262653A (ja) 先天性免疫不全症候群（エイズ）治療用組成物
Corbyn Plan launched to find HIV cure
Guvenc The impact of heptose phosphates on HIV latency and human immune responses
Yang CD8 T cells in HIV infection: mechanisms of immunity
De Villiers Acquired Immunodeficiency Syndrome A Forensic Perspective
Martyushev Modelling the dynamics of immune escape and latency in HIV infection
Martyushev Modelling the dynamics of immune escape and latency in HIV infection: implications for vaccination and treatment
Juelg et al. HIV CURE STRATEGIES
Lori Virostatics: A new frontier in the treatment of HIV/AIDS
Lederman Immune success and immune failure in HIV infection: implications for therapeutic intervention
Miller HYDROXYUREA: EIGHT YEARS'EXPERIENCE
Ferre Mucosal immune responses and their association with class I and class II HLA alleles in HIV-1 controllers
Ghourab AIDS: Biochemical prospectives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid